Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The value of circulating tumor cells for the staging of patients with NDMM

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the value of using circulating tumor cells (CTCs) in the prognosis of patients with newly diagnosed multiple myeloma (NDMM), highlighting the benefits of this approach over standard bone marrow assessments. Dr Paiva further comments on the feasibility and high reproducibility of this approach. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.